These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 23633630

  • 1. [Socioeconomic advantages of longer screening intervals for men with low prostate-specific antigen levels in prostate cancer mass screening].
    Kobayashi T, Goto R, Hinotsu S, Ogawa O.
    Hinyokika Kiyo; 2013 Mar; 59(3):159-66. PubMed ID: 23633630
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
    Bermúdez-Tamayo C, Martín Martín JJ, González Mdel P, Pérez Romero C.
    Urol Int; 2007 Mar; 79(4):336-44. PubMed ID: 18025853
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
    Nichol MB, Wu J, Huang J, Denham D, Frencher SK, Jacobsen SJ.
    BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
    [Abstract] [Full Text] [Related]

  • 5. Economic evaluation of prostate cancer screening with prostate-specific antigen.
    Imamura T, Yasunaga H.
    Int J Urol; 2008 Apr; 15(4):285-8. PubMed ID: 18380812
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ, Roobol DW, Schröder FH.
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH, Magnabosco WJ, Mauad EC, Carvalho AL.
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Heijnsdijk EA, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Tammela TL, Recker F, Denis L, Carlsson SV, Wever EM, Bangma CH, Schröder FH, Roobol MJ, Hugosson J, de Koning HJ.
    J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
    [Abstract] [Full Text] [Related]

  • 11. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
    Nanri M, Nanri K, Fujiyama C, Tokuda Y, Nakamura K, Uozumi J.
    Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
    [Abstract] [Full Text] [Related]

  • 12. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
    Keller A, Gericke C, Whitty JA, Yaxley J, Kua B, Coughlin G, Gianduzzo T.
    Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis.
    Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, Siebert U.
    Eur J Cancer; 2011 Jul; 47(11):1633-46. PubMed ID: 21482103
    [Abstract] [Full Text] [Related]

  • 14. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH, Raaijmakers R, Postma R, van der Kwast TH, Roobol MJ.
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [Abstract] [Full Text] [Related]

  • 15. Towards an optimal interval for prostate cancer screening.
    van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, Zhu X, Bangma CH, Schröder FH, Hugosson J.
    Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ, Grenabo A, Schröder FH, Hugosson J.
    J Natl Cancer Inst; 2007 Sep 05; 99(17):1296-303. PubMed ID: 17728218
    [Abstract] [Full Text] [Related]

  • 19. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
    Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R.
    JAMA Oncol; 2016 Jul 01; 2(7):890-8. PubMed ID: 27010943
    [Abstract] [Full Text] [Related]

  • 20. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
    Crawford ED, Abrahamsson PA.
    Eur Urol; 2008 Aug 01; 54(2):262-73. PubMed ID: 18556114
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.